Lactobacillus reuteri ： Bloating and Intestinal Gas

Q: Does Lactobacillus reuteri help with Bloating and Intestinal Gas?

Based on 7 studies with 500 participants, there is moderate evidence from clinical studies that Lactobacillus reuteri may support Bloating and Intestinal Gas management. Our evidence grade is B (Good Evidence).

Q: How much Lactobacillus reuteri should I take for Bloating and Intestinal Gas?

Studies have used various dosages. A commonly studied range is 100 million - 5 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.

Q: Are there side effects of Lactobacillus reuteri?

Reported side effects may include Mild gas in initial days of use, Occasional increased fussiness in infants during adjustment (transient), Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

Q: How strong is the evidence for Lactobacillus reuteri and Bloating and Intestinal Gas?

We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 500 total participants. The overall direction of effect is positive.

Multiple RCTs in breastfed infants show reduced crying time (50-70 min/day reduction). Well-established evidence for infantile colic but limited to infant population.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Dreuteri\u0026condition\u003Dbloating\u002Dand\u002Dgas'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

結論

Multiple RCTs in breastfed infants show reduced crying time (50-70 min/day reduction). Well-established evidence for infantile colic but limited to infant population.

Key Study Findings

basic science

Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA.

Dose: Lactobacillus reuteri E9 (dose not specified) vs: Placebo 効果: None < 0.05

Observational Study n=65 Open-label

Incidence and Characterization of SIBO in NAFLD Patients.

Dose: None vs: None Outcome: SIBO prevalence in NAFLD patients 効果: SIBO in 37%; post-treatment 4% remained+ None

対象集団: Adults with NAFLD diagnosed via FibroScan

Randomized Controlled Trial n=56 15 weeks Double-blind

Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and …

Dose: 4x10^8 CFU (induction), 2x10^8 CFU (standard) vs: Placebo Outcome: Constipation symptoms and QoL (Constipaq/CSS) 効果: None pP0.05

対象集団: Adults with functional constipation

Other n=54 Double-blind

Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, …

Dose: None vs: Simethicone Outcome: Safety and efficacy for functional bloating 効果: None pP0.008

対象集団: Adults with functional bloating

Meta-Analysis n=3122

Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a …

Dose: None vs: Triple therapy alone/placebo Outcome: H. pylori eradication rate and side effects 効果: None None

対象集団: Children with H. pylori infection

Randomized Controlled Trial n=101 16 weeks Double-blind

Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, …

Dose: L. reuteri DSM 17938 (1e8 CFU twice daily) vs: placebo Outcome: abdominal pain severity (Wong-Baker FACES) 効果: None None

対象集団: Children aged 6-15 with functional abdominal pain

Key Statistics

研究数

500

参加者数

↑

Positive

グレード

Referenced Papers

Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA. Other

Frontiers in bioscience … 2025

Incidence and Characterization of SIBO in NAFLD Patients. Other

Euroasian journal of … 2025

Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and bowel habit in functional constipation. RCT

Beneficial microbes 2018 35 件の引用

Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, randomised, double-blind, parallel group, clinical … Other

Translational gastroenterology and … 2018 24 件の引用

Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Meta-Analysis

European journal of … 2017 93 件の引用

Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial. RCT

The Journal of … 2016 84 件の引用

Probiotic vs. Placebo in Irritable Bowel Syndrome:A Randomized Controlled Trial. Other

Middle East journal … 2013 13 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:: 100 million - 5 billion CFU/day
infantilecolic:: 100 million CFU/day (DSM 17938 strain, 5 drops)
adultgisupport:: 1-5 billion CFU/day

上限量： Well-tolerated up to 10 billion CFU/day in clinical trials

研究で検討された用量

用量	期間	効果	N
Lactobacillus reuteri E9 (dose not specified)	--	Positive	--
None	--	Positive	65
4x10^8 CFU (induction), 2x10^8 CFU (standard)	15 weeks	Positive	56
None	--	Positive	54
None	--	Positive	3122
L. reuteri DSM 17938 (1e8 CFU twice daily)	16 weeks	Positive	101
None	4 weeks	Positive	--

推奨摂取タイミング： Before meals or on empty stomach; for infants, add drops to breast milk or formula

Safety & Side Effects

報告されている副作用

⚠ Mild gas in initial days of use
⚠ Occasional increased fussiness in infants during adjustment (transient)
⚠ Rare loose stools
⚠ Very rare: bacteremia in immunocompromised individuals

既知の相互作用

● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
● Immunosuppressants (theoretical risk in immunocompromised patients)
● Proton pump inhibitors (altered gastric pH may affect colonization)

耐容上限摂取量： Well-tolerated up to 10 billion CFU/day in clinical trials

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Lactobacillus reuteri help with Bloating and Intestinal Gas?

Based on 7 studies with 500 participants, there is moderate evidence from clinical studies that Lactobacillus reuteri may support Bloating and Intestinal Gas management. Our evidence grade is B (Good Evidence).

How much Lactobacillus reuteri should I take for Bloating and Intestinal Gas?

Studies have used various dosages. A commonly studied range is 100 million - 5 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Lactobacillus reuteri?

Reported side effects may include Mild gas in initial days of use, Occasional increased fussiness in infants during adjustment (transient), Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Lactobacillus reuteri and Bloating and Intestinal Gas?

We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 500 total participants. The overall direction of effect is positive.

Related Evidence

に関する他の成分： Bloating and Intestinal Gas

Pancreatic Enzymes (Pancrelipase) A Ginger B Alpha-Galactosidase B Medium-Chain Triglycerides (MCT Oil) C

Lactobacillus reuteri 他の症状・状態について

Gastroesophageal Reflux Disease (GERD) C

総合評価

Multiple RCTs in breastfed infants show reduced crying time (50-70 min/day reduction). Well-established evidence for infantile colic but limited to infant population.

Evidence Strength72%

High confidence

研究の内訳

RCT (2)Meta (1)Other (4)

代替成分との比較

この症状に対する他の成分との比較をご覧ください。

に関するすべての成分を見る： Bloating and Intestinal Gas

詳しく見る

FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。